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Abstract 
Neuraxial agents provide robust pain control, have the potential to improve outcomes, and are an 
important component of the perioperative care of children. Opioids or clonidine improve analgesia 
when added to perioperative epidural infusions; analgesia is significantly prolonged by addition of 
clonidine, ketamine, neostigmine or tramadol to single shot caudal injections of local anesthetic; 
and neonatal intrathecal anesthesia/analgesia is increasing in some centers. However, it is 
difficult to determine the relative risk-benefit of different techniques and drugs without detailed 
and sensitive data related to analgesia requirements, side-effects, and follow-up. Current data 
related to benefits and complications in neonates and infants are summarized, but variability in 
current neuraxial drug use reflects the relative lack of high quality evidence. Recent preclinical 
reports of adverse effects of general anesthetics on the developing brain have increased 
awareness of the potential benefit of neuraxial anesthesia/analgesia to avoid or reduce general 
anesthetic dose requirements. However, the developing spinal cord is also vulnerable to drug-
related toxicity, and although there are well-established preclinical models and criteria for 
assessing spinal cord toxicity in adult animals, until recently there had been no systematic 
evaluation during early life. Therefore, the second half of this review presents preclinical data 
evaluating age-dependent changes in the pharmacodynamic response to different spinal 
analgesics, and recent studies evaluating spinal toxicity in specific developmental models. Finally, 
we advocate use of neuraxial agents with the widest demonstrable safety margin and suggest 
minimum standards for preclinical evaluation prior to adoption of new analgesics or preparations 
into routine clinical practice. 
 
Introduction 
The consequences of inadequate regulation of pain were made evident by early clinical studies 
showing that anesthesia and analgesia reduced morbidity and mortality following cardiac surgery 
in the newborn1,2. As well as deleterious acute physiologic consequences, there is an evolving 
literature indicating that neonatal surgery and/or intensive care can result in prolonged changes 
in sensory processing3–6 and altered responses to future pain7–9. While adequate intra-
operative anesthesia and analgesia in the newborn, as in the adult, can be achieved by inhalants 
and intravenous drugs, there has long been an appreciation of the benefits of neuraxial 
anesthetics and analgesics, which can create dense local anesthesia and analgesia that extends 
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into the perioperative period with reduced systemic side effects. The use of neuraxial drugs in the 
control of pain may now be further encouraged as recent data demonstrate that general 
anesthetics (NMDA antagonists, isoflurane, nitrous oxide) and benzodiazepines produce 
developmentally regulated increases in perinatal apoptosis and long term deleterious behavioral 
changes 10–12. However, it is important to appreciate that neuraxial delivery employs agents 
which until recently have never been systematically assessed for their safety during early 
development. This has been highlighted by the Anesthetic and Life Support Drugs Advisory 
Committee of the FDA*, which stated that “the potential for anesthetic agent-induced 
neurodegeneration at the level of the spinal cord should be evaluated, particularly with respect to 
the local anesthetics and opioids administered neuraxially”. 
 
An increasing number of drugs and preparations have been used to produce neuraxial analgesia, 
with clinical studies demonstrating tolerability and efficacy. However, high quality evidence for 
improved clinical outcomes, particularly in neonates and infants, is limited. There is a growing 
emphasis on the need for preclinical evaluation of spinal toxicity to fully evaluate the relative 
benefits and risks of different agents prior to clinical use. This is reflected by the adoption of 
specific guidelines for publication of neuraxial clinical trials by several major journals. In this 
review, we seek to address four specific issues: 1) summarize the clinical use of neuraxial 
techniques in neonates and infants; 2) highlight current difficulties in evaluating the comparative 
benefit and potential risk of different spinal analgesic drugs; 3) summarize preclinical models 
evaluating developmental changes in the pharmacodynamic response to spinal analgesic drugs; 
and 4) review minimal standards for implementation of spinal agents in neonates to permit 
informed assessment between different agents in terms of efficacy and toxicity in the neonate. 
The review will consider agents that block conduction (i.e. local anesthetics), but will focus on 
those that specifically attenuate the spinal processing of pain information when administered by 
the intrathecal or epidural/caudal route (i.e. spinal analgesics, also often termed spinal adjuvants). 
 
Clinical use of neuraxial analgesia and anesthesia in neonates and infants 
Neuraxial delivery 
The control of afferent traffic through neuraxial interventions (epidural or intrathecal delivery) can 
be utilized in neonates and infants as (i) a sole neuraxial anesthetic technique for abdominal and 
lower limb surgery 13,14; or (ii) as a supplement to reduce intraoperative general anesthetic 
requirements and manage peri-operative pain15,16. 
 
Intrathecal delivery of local anesthetic produces “spinal” anesthesia. Use of neonatal spinal 
anesthesia is increasing in some centers17,18, with large series reporting safe and effective 
anesthesia and analgesia13,19,20, including use in high risk and extremely low birth weight 
neonates21. “Single shot” spinal anesthesia provides an alternative to general anesthesia for 
lower abdominal or inguinal surgery, however the clinical utility of this technique is limited by the 
duration of action of intrathecal local anesthetics in neonates, and conversion to general 
anesthesia is often required if surgical duration exceeds one hour13,19. Various techniques have 
been utilized in infants and neonates to prolong the duration of intrathecal anesthesia including: 
(i) repeat administration via an intrathecal catheter22; (ii) a combined spinal and epidural catheter 
(CSE) technique for upper abdominal surgery23,24; (iii) additional local anesthetic administration 
by the surgeon during myelomeningocoele surgery; and (iv) addition of spinal analgesic adjuvants 
such as opioids22,25 or clonidine26,27. 
 
Epidural analgesia can also be used as a sole technique 28,29 or as a supplement to general 
anesthesia for perioperative analgesia 30 for neonatal and infant surgery. Single bolus 
administration 15, or infusion via a catheter advanced from the caudal space 31 or inserted at an 
intervertebral level in the thoracic or lumbar spine 32 is possible in even the smallest preterm 
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neonate 33. A range of spinal analgesics are now administered, often in conjunction with local 
anesthetics, with the aim of: (i) improving analgesia; (ii) reducing local anesthetic requirements 
and associated side-effects such as motor block; and (iii) prolonging analgesia following single 
shot administration. 
 
Epidemiology 
Neuraxial analgesia is used in children of all ages, but the pattern of use and choice of technique 
varies with age of the child, across institutions, and with time in some centers18,34. In a 1994 
survey of regional anesthesia by the French-language Society of Pediatric Anesthesiologists 
(ADARPEF), neonates comprised 3.3% of the pediatric population, but received 3.4% of caudals, 
1.8% of epidurals, and 10.9% of all spinal anesthetics.34 A similar survey in 2006 found a 
decrease in the use of caudals, but increased use of epidural catheters and single shot spinal 
anesthetics, and a greater proportion of central blocks were being performed at younger ages 
(5.6 vs 3.4% in neonates; 30 vs 16.5% in infants < 6 months).17 In one French center, the overall 
proportion of neuraxial blocks decreased from 1989 to 2005, but spinal anesthetics in neonates 
had become the most frequent technique, comprising 30% of the total18. The number of epidurals 
performed annually in UK children was stable from 2002 to 2005, with 5% of the total 10633 
epidural performed in neonates and 16% in children aged between 1 month and 1 year 35. 
 
Clinical benefits and risks of neuraxial analgesia 
Potential advantages of neuraxial route in neonates and infants 
In addition to minimizing the potential exposure of the developing brain to general anesthetics, 
neuraxial analgesia may improve postoperative outcomes for high-risk neonates who are 
susceptible to respiratory complications (e.g. preterm born neonates with lung disease and 
postoperative apnea) 36 or who require major surgery for correction of congenital anomalies 37–
40. However, the magnitude of benefit of intra-operative or peri-operative neuraxial anesthesia is 
difficult to determine from case reports or series 41. Even in older children undergoing scoliosis 
surgery, meta-analysis demonstrated improved analgesia with epidural local anesthetic and 
opioid versus systemic opioid for adolescents, but there was insufficient data to confirm any 
change in respiratory outcomes, length of hospital stay, or mortality 42. In younger children, 
variability in study design (type of surgery; neuraxial anesthesia regimes with local anesthetic in 
varying concentrations and doses and different types and doses of spinal analgesic) makes 
systematic analysis of outcomes even more difficult. Reported benefits of neuraxial anesthesia in 
studies that include neonates and infants are: 
 
Reduction in respiratory complications 
i. post-operative apnea. Analysis of four trials comparing spinal and general anesthesia in 
neonates born preterm undergoing inguinal herniorrhaphy found a reduction in the 
incidence of postoperative apnea only if systemic sedatives were avoided 36. Neuraxial 
anesthesia and avoidance of opioids may have added advantages in neonates with central 
hypoventilation syndromes 43. It has been suggested that spinal anesthesia can reduce 
costs related to postoperative monitoring and hospitalization 44. 
ii. post-operative mechanical ventilation. In a randomized trial of infants undergoing cardiac 
surgery, caudal morphine and local anesthetic provided some analgesic benefits over 
systemic morphine, but the study had insufficient power to evaluate effects on early 
extubation 45. In case series comparing perioperative neuraxial anesthesia with systemic 
opioid analgesia, the proportion of neonates requiring postoperative mechanical 
ventilation was reduced following gastrochisis repair 38, lung resection for congenital lung 
lesions 46, and Nissen fundoplication 47. Cases of improved respiratory function following 
major neonatal thoracic surgery with epidural analgesia have been reported 48,49. 
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Attenuation of stress response 
Circulating levels of stress hormones such as cortisol 50,51, adrenaline and noradrenaline 22,52 
are reduced when supplementary neuraxial anesthesia is added to general anesthesia. 
 
Cardiac stability 
Maintenance of cardiovascular stability has been demonstrated during neuraxial techniques in 
neonates 53, including CSE anesthesia for upper abdominal surgery 24 and in high-risk neonates 
and infants with congenital cardiac disease 54. While these observations support the safety of 
the technique, improved outcomes in comparisons with general anesthesia have not been 
confirmed. 
 
Reduction in hospital stay 
In uncontrolled trials, epidural rather than systemic analgesia reduced hospital stay following 
ligation of patent ductus arteriosus in infants 55 and fundoplication 47. 
 
Improved surgical outcome 
Wound dehiscence following bladder exstrophy repair in neonates was avoided with prolonged 
neuraxial anesthesia (mean 15 days) and sedation, but there was no comparison with other 
analgesic techniques 37. 
 
 
Potential disadvantages of neuraxial route in neonates and infants 
Complication Rates 
Although severe complications following pediatric neuraxial techniques are rare, the incidence is 
higher in neonates and infants: 0.4% vs 0.1% for all neuraxial blocks 17 and 1.1% vs 0.49% for 
epidural blocks alone 35. Outcomes may be worse in neonates 56,57, with complication rates as 
high as 4:1000 (including 3 deaths) 56 initially reported, but more recent surveys report 
complication rates of 0.29% (95%CI: 0.21–0.43) for central blocks (caudal, epidural and spinal; 
n=10,556) 17. Following peri-operative epidural infusions (n=10,633), the rate of serious incidents 
approximated 0.5:1000, with an additional 0.75:1000 incidents graded as moderate severity 35. 
 
The clinical practice setting, resource availability, and experience of individual practitioners can 
have a major impact on the relative risk and benefit of neuraxial anesthesia. The lack of intensive 
care facilities in some practice settings will increase the potential benefit of neuraxial techniques 
that reduce the requirement for postoperative mechanical ventilation. Management by 
experienced practitioners may minimize the incidence and severity of adverse events in neonates, 
as skilled intraoperative resuscitation was required following dural puncture or intravascular 
injection 34. Complications related to the use of wrong equipment (eg. inappropriate or oversized 
needles, excessive length of catheter introduced into space) were reported in early series 34. 
Pump programming or prescription errors were more common in young children (0.3% in children 
under 1 year versus 0.07% in 1–8 year-olds) 35. All were corrected before harm occurred, but 
this emphasizes the need for adequate monitoring and follow-up of patients with epidural infusions 
 
Infection 
Asymptomatic colonization of epidural catheters is common (35%) but in series of 210 58 or 1458 
children 59, no local or systemic infections were reported. Age was not a clear factor, although 
the rate of colonization was higher for caudal than lumbar catheters in the under 3 year age group 
58. In a national audit of 10,633 perioperative epidural infusions, there were 25 cases of local skin 
infection (ages not reported); epidural abscess was reported in 2 cases (including one infant), and 
an additional 16 year old patient developed signs of meningism 35. In a single center over 17 
years, epidural catheter related infection, limited to the paraspinal or subcutaneous tissue, 
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occurred in 6 of 10,437 (0.06%) cases, including one neonate and one infant 60. All presented 
with back pain, pyrexia, and cellulitis; 5 also had pus visible at the catheter exit site; 3 required 
surgical drainage; and all recovered without neurological sequelae. Epidural catheters inserted 
for longer periods for chronic pain management were associated with higher rates of infection 
(3.2% vs 0.06%) 60. 
 
Neurological injury 
Rates of neurological injury following neuraxial analgesia range from 0.13 to 0.4 per 1000 in large 
series, with higher rates following epidural catheter techniques than single shot caudals. Transient 
neuropathy was reported following 2 per 15,013 central blocks34 and 6 per 10,633 epidural 
anesthetic infusions35. In addition, following a programming error that rapidly delivered 15ml of 
solution, a 4-month-old preterm born infant developed cauda equina syndrome with persisting 
neurological deficit one year later35. Suspected nerve injuries occurred following 1 of 364 
thoracic, 2 of 1183 lumbar, and 1 of 8493 caudal epidural blocks, with no reported long-term 
deficits, and children were aged 8 years and above17. Isolated cases of neurological deficit 
following neuraxial anesthesia of varying severity have been reported in neonates61 and older 
children62–65. The relative contributions of needle trauma, surgical injury, or potential drug-
related toxicity to neurological injury are difficult to determine. No neurologic sequelae were 
reported in a retrospective review of 750 children (52% of whom were infants) requiring cardiac 
surgery and treated with peri-operative epidural local anesthetic, opioid and/or clonidine 66. 
However, as in many studies, the duration of follow-up and the nature and sensitivity of 
neurological evaluation was not reported. The rates of complications may be under-estimated, 
particularly in young children 67, who cannot report sensory symptoms and subtle motor changes 
are difficult to detect in infants not yet walking. More thorough follow-up of patients following 
neuraxial blocks has been advocated 68. 
 
Clinical choice of a spinal analgesic: efficacy 
Local anesthetics 
The primary drugs delivered neuraxially in neonates are local anesthetics and examples of the 
range of preparations used in neonates and infants are included in Table 1. Issues of safety with 
neuraxially administered local anesthetics have tended to focus on systemic toxicity and high 
plasma concentrations that precipitate neurological and cardiovascular complications (i.e. 
convulsions and arrhythmias) 69,70. Age-related alterations in pharmacokinetics result in higher 
free drug concentration following a bolus and accumulation of local anesthetic during infusion in 
neonates 71–75. As a result, infusion duration tends to be limited in the youngest patients. In a 
recent study of neonates following bladder exstrophy repair, epidural lidocaine was infused for an 
average of 15 days (range 4–30 days), but with regular monitoring of plasma lidocaine 
concentration 37. As will be reviewed below, it should be emphasized that although widely 
employed, there have until recently been no systematic studies as to potential adverse effects 
upon the developing spinal cord 76, and no comparative studies of different local anesthetics. 
 
Spinal analgesics and clinical study design 
Few studies have directly compared the efficacy of different spinal analgesic drugs in children of 
different ages. This, and the lack of systematic safety data (discussed below), makes it difficult 
for practitioners to make an evidence-based choice between different drugs, thus contributing to 
the wide variability in current clinical practice 77,78. 
 
Evaluating data from current controlled trials is hampered by variation in methodology, particularly 
in the sensitivity of the outcome measures and end-points used to measure the duration and 
efficacy of analgesia. In neonates and infants, sample sizes are frequently small 79,80 as 
recruitment of large homogeneous samples is difficult, and may be further constrained by ethical 
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issues 81. Additional variability in the type, sensitivity and specificity of pain assessment tools 
utilized 78 may further reduce the power of the study. 
 
Prolongation of analgesia 
If analgesia is being titrated against individual requirements, differences in pain scores should not 
be seen, and therefore differences in the duration of analgesia or supplemental analgesia 
requirements are often used as outcome measures. The most frequent comparison is between 
the same dose of local anesthetic with or without a spinal analgesic, and relatively few studies 
evaluate the ability of spinal analgesics to reduce the required concentration of local anesthetic 
82,83 or the impact of different doses of local anesthetic 84. Time to first analgesia will be 
influenced by: the sensitivity, frequency and inter-rater reliability of pain assessment (particularly 
following discharge when reliance is placed on parental interventions); the trigger for 
administration; and the type of supplemental analgesic. Meta-analyses have demonstrated 
statistically significant prolongation of analgesia with caudal clonidine 79,85,86 and ketamine 
84,87. The remaining question is whether the degree of change is clinically, as well as statistically, 
significant. As reported increases in duration range from 2.3 to 5.3 hours, analgesia may be 
receding soon after the patient leaves the PACU or when ambulatory patients are leaving the 
hospital, and this needs to be considered when providing instructions to ward staff and parents 
regarding supplemental analgesia. 
 
Supplemental analgesia 
The clinical significance of a reduction in supplemental analgesia as an outcome depends on the 
total dose, side-effect profile and relative risk of the different treatments. A reduction in opioid 
requirement with addition of spinal analgesics88 has the potential to reduce opioid-related side-
effects such as nausea and vomiting. However, many pediatric studies have been conducted 
following day case surgery, where postoperative pain scores and/or analgesic requirements are 
low, making it difficult to demonstrate a difference between two active treatments89. A reduction 
in the use of mild analgesics such as acetaminophen or NSAIDs84,87 provides evidence of an 
analgesic effect, but the relative risk of the spinal adjuvant must be weighed against that of the 
additional supplemental analgesia. We would question whether avoiding one or two doses of 
acetaminophen over a 24-hour period justifies the risk of neuraxial administration of a drug that 
has not been evaluated for spinal toxicity. In addition, studies may report only the proportion of 
children requiring analgesia, or the total number of doses in the whole treatment group, and 
therefore dose requirements and relative benefits or risks for individual patients cannot be 
assessed. 
 
Route of administration 
Neuraxial analgesic administration has the potential to produce analgesia at doses lower than 
required with systemic administration, thus reducing side-effects. Epidural morphine (12–
50mcg/kg) improves analgesia 90–92, and although early systemic absorption was detected, 
analgesia was evident 1 and 3 hours later when plasma levels were lower than required for a 
systemic analgesic effect 88. Lower doses (2–5μg/kg) are effective intrathecally 93–95. The 
degree of dose sparing depends on the chemical properties of the drug, and for more lipophilic  
opioids such as fentanyl, the difference between equi-effective intrathecal, epidural and systemic 
doses may be less96. Minimal dose sparing has also been demonstrated with ketamine, as 0.5 
to 1mg/kg is utilized in caudal studies 97,98 and the same dose systemically provides procedural 
sedation and analgesia 99–101, albeit for a shorter duration 102. Similarly, analgesia was 
prolonged when comparing caudal and intravenous administration of 2mg/kg tramadol 103. 
Clonidine via the intrathecal 104 or caudal 105 route has a greater effect on analgesic duration 
than the same dose intravenously, but effects on general anesthetic requirements and early post-
operative sedation are seen with neuraxial and systemic administration. 
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Addition of caudal adjuvants following unilateral hernia repair in children often aims to reduce 
local anesthetic requirements and associated motor block, but less invasive techniques such as 
local infiltration and ilioinguinal block are also effective in the early postoperative period 78. Few 
studies have directly compared different local anesthetic techniques. When compared to dorsal 
penile block for circumcision, caudal bupivacaine plus ketamine was found to have no advantage 
106, or to produce mild prolongation of analgesia (7.6 vs 6.2 hrs) at the cost of increased motor 
block 107. 
 
Spinal analgesic drugs 
In the following section we will provide a commentary on the use of analgesics that are delivered 
by the intrathecal or epidural/caudal route, with the aim of producing spinally-mediated analgesia 
(i.e. spinal analgesics or spinal adjuvant analgesic drugs), and which are typically used in 
conjunction with local anesthetics. Table 1 provides a systematic summary of the reported 
literature relevant to the several families of adjuvant analgesics. In each case, the reported dosing 
is provided. In many cases there is limited information related to the concentration of the different 
drugs within the injectate, but when co-administered with local anesthetic, the desired spread and 
volume of local anesthetic is often the deciding factor. 
 
Opioids are the most frequently utilized spinal analgesics, but increased knowledge of spinal 
pharmacology has led to drugs such as alpha-2 adrenergic agonists (clonidine), NMDA 
antagonists (ketamine), GABA agonists (midazolam) and neostigmine being used alone or in 
combination as spinal analgesics in adults 108. Use of spinal analgesics has expanded to 
pediatric practice, but there is marked variability in the availability of different preparations and in 
the clinical use of these drugs. Surveys of pediatric anesthetists in the UK reported that 16% 
added clonidine, 15% ketamine and 9% epinephrine to epidural infusions 77. The proportion using 
clonidine as a caudal analgesic has increased (26% in 2002 and 42% in 2009), whereas use of 
ketamine and midazolam remained relatively constant at 32–37% and 0.5–1% 
respectively109,110. A survey of 25 international pediatric centers found an increase use of 
clonidine (18 to 23 of 25 centers) whereas use of ketamine had significantly decreased from 12 
to 4 centers 111. While the majority of controlled trials have been conducted in children over 6 
months of age 79, many spinal analgesics have been used in neonates and infants less than 6 
months (see Table 2), despite limited evaluation of age-related changes in the pharmacodynamic 
profile of these drugs and no systematic evaluation of toxicity in the developing spinal cord. 
 
Opioids 
Mu opioids have been administered by epidural bolus and/or infusion and also as an intrathecal 
additive with local anesthetic. Morphine or fentanyl has been used most frequently in neonates 
and infants 22,25,30, but the use of a wide range of opioid drugs has been reported in children 6 
months and older including: alfentanil 112, sufentanil 113–115, buprenorphine 116, butorphanol 
117–119, diamorphine, 120,121, hydromorphone 122 and tramadol 103,123–127. In surveys of 
UK pediatric anesthetists, 85% used opioids for epidural analgesia77, but variability in the agent 
chosen (fentanyl, morphine, or diamorphine) was noted in this and an earlier survey (21% adding 
fentanyl and 13% adding diamorphine to caudal anesthetic blocks) 109. Although many 
practitioners had a minimum age for the use of epidural opioids, the cutoff varied from the neonatal 
period to 5 years of age 77. 
Clonidine and Dexmedetomidine 
Meta-analyses of caudal studies in children over 6 months of age, reported prolongation of 
analgesia with addition of 1–2μg/kg clonidine to local anesthetic for 2.4 (95%CI:2.6–5.5) hours 
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79, 3.98 (95% CI: 2.84–5.13) hours 85 and 3.68 (2.65–4.7) hours 86. Many studies reported 
minor sedation following clonidine, which was more severe and associated with cardiovascular 
side-effects at higher doses (5μg/kg) 79. Case reports of side-effects of apnea, oxygen 
desaturation, and bradycardia have been reported in neonates given doses of caudal clonidine 
(1.25–2.2 mg/kg) that are tolerated by older children 128–130. Continuous infusion of epidural 
clonidine 0.08–0.12 μg/kg/hr produces dose-dependent analgesia when added to local 
anesthetic infusions 131, and higher doses of clonidine alone (0.2μg/kg/hr preceded by bolus of 
2μg/kg) provide analgesia at rest following abdominal surgery 132. When added to intrathecal 
local anesthetic in neonates relatively large doses of clonidine (up to 2mcg/kg) prolonged 
analgesia 26. A subsequent observational study with longer follow-up (24 hrs) found over half of 
the patients were sedated in the immediate postoperative period, and the proportion of 
neonates developing self-limiting apnea increased postoperatively 27. This dosing represents 
concentrations up to 5mcg/ml being utilized for both caudal and intrathecal single shot injections 
and 0.6 to 1mcg/ml for continuous epidural infusion. 
 
The more selective alpha2-adrenergic agonist dexmedetomidine (1μg/kg) prolonged analgesia 
when added to caudal bupivacaine, and reduced supplemental analgesic requirements by 1–2 
doses of acetaminophen 10mg/kg in the first 24 post-operative hours 133. Similar analgesia 
was reported when comparing caudal dexmedetomidine and clonidine in children aged 6 
months and above 134. As there has been limited evaluation of neurotoxicity with this drug135, 
further testing is required before routine clinical use 136. 
Ketamine 
Caudal ketamine has been utilized for perioperative analgesia in children, including neonates and 
infants 84,87,97,98,137. Dose ranging studies using 0.25–1mg/kg reported 0.5mg/kg as the 
optimum dose, with increasing side-effects at 1mg/kg 83,138–140. Recent meta-analyses 
evaluating addition of ketamine to caudal local anesthetic reported prolongation of analgesia for 
2.26 hours (95%CI:1.53–2.98) 87 or 5.3 (95%CI:5.45–5.76) hours 84. Acute psychomimetic 
effects were reported in 2 of 7 trials 84, but the difference was not statistically significant in the 
other analysis (OR=1.72, 95%CI:0.69–4.26) 87. A reduction in supplementary analgesics was 
demonstrated in studies utilizing non-opioid analgesics 87 or acetaminophen (paracetamol)84, 
but not in studies where peri-operative opioids were required 87. Ketamine 0.5–1mg/kg was 
diluted with 0.5–1.0 mls/kg of local anaesthetic or saline resulting in final concentrations 
approximating 0.5–1.3mcg/ml 137,139,141. 
 
Systemically administered S-ketamine has increased potency over the racemic mixture 100. Dose 
sparing has not been evident in caudal studies, with s-ketamine utilized in doses of 0.5mg/kg 
142,143 or 1mg/kg 102,141,144. Ketamine solutions may contain benzethonium chloride 145, but 
there is limited information about the injectate preparation in some studies 112,146,147, while 
others report using a preservative free solution of racemic 106,107,138,139,148,149 or S-
ketamine 97,98,137. In some regions, the number of centers using neuraxial ketamine in children 
has reduced in recent years 111,150. 
 
Midazolam 
Midazolam is a GABA-A agonist with potential analgesic actions in the spinal cord, but major 
concerns have been raised about the safety of neuraxial administration in both adult 151,152 and 
pediatric practice 153. Addition of midazolam 50 μg/kg to caudal local anesthetic prolongs 
analgesia and increased sedation in children aged 1–12 years 154. Some reports employ a 
preservative-free solution 148,155, but others give no details of the pharmaceutical preparation 
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154,156 although one reported using a solution with a pH of 6.2 rather than 3.3–3.9 as used in 
previous studies 157. Solutions of 0.1–0.5% midazolam were administered with 0.5–1.0ml/kg of 
local anaesthetic or saline resulting in final concentrations approximating 50–100 mcg/ml 
154,155,157,158. 
 
Neostigmine 
Neostigmine produces analgesia following neuraxial administration in adults 159,160, but the 
incidence of side-effects has led to its role in pediatric practice being questioned161. Doses of 
caudal neostigmine ranging from 1 to 4 μg/kg have been administered in children from 5 months 
of age 162–166 and prolong analgesia by 9.9hrs (95%CI: 7.8–12.2hrs) but without a clear dose-
response relationship 86. The relative risk of PONV is significantly increased (RR 1.78, 95%CI: 
1.11–2.85] 86, with incidences from 30% 167 and up to 60% with higher doses 168. Preparations 
containing methylparaben and propylparaben 148,169 and preservative free solutions 170 have 
been utilized. Prolongation of hyperbaric bupivacaine block has also been demonstrated with 
intrathecal neostigmine 0.75–1mcg/kg in infants 171. This dosing represents concentrations of 2–
4mcg/ml for caudal injections and 10mcg/ml administered intrathecally. 
 
Clinical choice of spinal analgesic: safety 
For the last two decades, there has been an increasing appreciation that there needs to be a 
specific intent to define the safety of neuraxially delivered drugs prior to routine clinical use in 
adults 172,173. We, and others, have argued that systematic preclinical assessment of potential 
for spinal toxicity in validated models should be performed before clinical delivery into the 
neuraxial space of neonates and children 150,161. Without safety data, it is impossible to confirm 
a favorable risk-benefit ratio for neuraxial administration, or to compare the relative safety, of this 
wide range of drugs and preparations, and clinical trials must be undertaken with caution. So 
significant has become this issue, that several major journals involved in pain and anesthesia 
have provided specific guidelines on the acceptability of work that employs the off-label neuraxial 
use of novel agents, indicating that systematic preclinical safety should be available or specific 
FDA approval gained prior to undertaking the trial 174–177. In the following sections, we review 
the information that does exist regarding spinal adjuvant use in human infants; but we emphasize 
that in and of itself, such information does not qualify the agent being delivered as safe. Often it 
reflects retrospective series, limited follow-up, and the primary metric of the safety study (i.e. 
spinal histopathology) cannot be assessed. 
 
Evaluation of risk 
Concerns regarding the potential for toxicity following neuraxial analgesic administration have 
been raised in multiple reviews and editorials with calls for further preclinical testing. “It is essential 
to undertake extensive animal testing with further evaluation of any neurotoxic effects prior to 
pediatric use” 79. “Before epidural midazolam is routinely used for surgery in children, more 
extensive testing of its use in animals should be completed”.. and “although the extensive 
preclinical testing may seem burdensome, the risk-benefit relationship for epidural midazolam 
justifies the need” 153. Although preservatives in preparations of neostigmine 178 and ketamine 
179 may contribute to potential toxicity, using a preservative-free solution does not guarantee 
safety. Authors reporting the use of caudal ketamine acknowledge that “as yet, no permanent 
neurological injury has resulted from single-shot caudal ketamine use but caution is warranted” 
97, and that conclusive safety studies are required 84,100. This is particularly important as 
isolated cases of post-operative neurological injury have been reported in children, and neuraxial 
analgesia may be implicated in medicolegal claims even if other potential factors (such as 
peripheral compression neuropathy related to positioning) are subsequently identified 180. 
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It was suggested several years ago that performance of neuraxial anesthesia in healthy children 
required demonstration of a high therapeutic ratio and additional advantages 181. Although 
complications are rare 35, without information regarding tissue toxicity it is difficult to determine if 
the drug administered contributes to the risk. Extensive clinical use does not preclude the potential 
for cases of toxicity 79, as seen in adult practice with chloroprocaine 182 and lidocaine and cauda 
equina syndrome 183. It has also been noted that a single case of neurological injury may be 
sufficient to change clinical practice, bring a particular technique in general into disrepute, and 
thus deny many children the benefits of neuraxial analgesia 161. Therefore, further specific data 
comparing the efficacy and relative safety of currently available and potential new spinal analgesic 
agents is essential to inform clinical choice. New alternatives should only be used if improved 
analgesia, combined with an acceptable safety and side-effect profile, can be demonstrated 161. 
It should be stressed that the neuraxial route of delivery exposes local tissues (meninges, roots, 
spinal parenchyma) to extraordinary concentrations of agent (mg/mL), which because of local 
restrictions in redistribution may persist for extended intervals. Accordingly, the specific 
assessment of the potential toxicity of the agent must be of the highest priority. In the following 
sections we will review the existing preclinical data related to the safety of spinal anesthetic and 
analgesic agents in neonatal models. 
 
Preclinical models of neuraxial anlagesia: developmental pharmacodynamic responses 
Neonatal neuraxial delivery models 
 
Intrathecal and epidural delivery techniques 
Bolus intrathecal drugs in neonatal and infant rats can be performed with a technique similar to 
that described in adult mice 184. The spinal column or pelvic girdle is stabilized by one hand, and 
percutaneous injection is performed at the level of the cauda equina in the L5/6 interspace 
(rodents have 6 lumbar vertebrae) with a 30-gauge needle attached to a syringe calibrated to 
deliver microliter volumes. Correct placement is typically demonstrated by a tail flick on needle 
insertion. While it is likely that such a response represents contact with a nerve root and is a 
potential source of pathology 185, appropriate control studies in neonatal rats have revealed no 
untoward anatomic pathology related to this technique 186. Systematic training with the injection 
of dye and confirmation of spread within the CSF on post-mortem dissection ensures that each 
experimenter can consistently perform the technique 184,186. In addition, we recently used in 
vivo imaging following intrathecal injection of a fluorescent dye to confirm that our technique was 
reliable and reproducible in rat pups as young as 3 postnatal days that have an average weight 
around 10 grams 186. 
 
Intrathecal catheters have been inserted via a lateral thoracic laminectomy in pups as young as 
P3. An injectate volume of 4μL of methylene blue produces spread from the caudal cervical to 
lumbar/sacral region 187, but associated motor deficits limit behavioural analysis to the 
contralateral limb. 
 
Single shot percutanenous epidural injections can also be performed in rat pups, with correct 
epidural placement (spread along vertebral segments but lack of staining in CSF) is confirmed by 
co-injection of Evan’s blue and post-mortem dissection 188–190. 
 
Distribution of injectate 
The distribution of the neuraxially delivered agents must be defined in any preclinical model. The 
volume must be adequate to deliver agent to the appropriate dermatomes used to evoke pain 
behavior (e.g. lumbar segments for evaluation of hindlimb withdrawal reftex sensitivity) but 
insufficient to acutely produce supraspinal redistribution. Recently, we confirmed that segmental 
spread of intrathecal dye co-varied directly with injectate volume and inversely with age in rat 
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pups 186. An injectate volume of 0.5 μL/g produced spread across a median of 9, 7 and 5 
segments at P3, P10 and P21 respectively. Increasing the volume to 1μL/g increased spread 
(median number of segments 16 vs 9 at P3, 13 vs 7 at P10). This was confirmed with in vivo 
imaging, and larger injectate volumes of 1.5 μL/g resulted in fluorescent dye extending into the 
cisterna magna and supraspinal cisterns 186. 
 
The extent of epidural spread has also been related to the volume of injectate in several species 
191–193. Similarly in rat pups of different ages, injectate volumes have been based on body 
weight, and reflect the increasing volume of the elongating spinal canal. In neonatal rat pups, 
epidural administration of approximately 2 μL/gram of dye 188–190 produces spread to the mid-
thoracic region following low lumbar injection. 
 
Radioactive labeling in the spinal cord has also been used to characterize neuraxial injections. 
Percutaneous intrathecal injection of 2 μL in P3, or 7 μL of 3[H]-gabazine in P21 rats, produced 
binding throughout the thoracolumbar cord 194. Epidural injection of 3[H]morphine at P3, P10 or 
P21 produced similar levels of binding in the cord, all of which, as expected were much lower than 
levels seen following systemic administration of the same dose 189. 
 
An important indirect assessment of correct placement is the observation of an appropriate 
behavioral response following injection of an analgesic or local anesthetic. While overly large 
volumes promoting supraspinal redistribution are to be avoided, very small volumes may in fact 
lead to an inadequate movement of the injectate to the spinal segments regulating the processing 
of afferent traffic. Accordingly, demonstration of a reliable and dose-dependent change in pain 
behavior is a critical component of validating dosing volumes in a preclinical model. Neuraxial 
local anesthetic effects may be assessed by motor and/or sensory changes, and thoracolumbar 
spread can be assumed by maintenance of adequate respiration, motor block restricted to the 
hindlimbs and/or lack of a hindlimb withdrawal response to a suprathreshold stimulus 76,186. 
 
Developmental pharmacodynamic profile of spinal analgesics 
We have postulated that evaluation of the relative safety (or toxicity) of different spinal agents is 
best made in the context of the therapeutic ratio i.e. the dose that produces toxicity or the 
maximum tolerated dose versus the dose that is required to have a therapeutic analgesic effect 
186,195,196. Accordingly, it is appropriate to consider the utility of neonatal models of neuraxial 
delivery in defining dose-related analgesic and behavioral effects. Developmentally-regulated 
changes in the structure and function of nociceptor pathways, and in the expression and 
distribution of receptors, have a significant impact on analgesic efficacy and dose requirements 
during postnatal life 197. Studies in developmental models, particularly the rat pup, allow 
systematic assessment of a variety of specific nociceptive end-points and the degree of alteration 
by analgesic agents. 
 
Analgesic efficacy and age-dependent dosing 
Increases in the mechanical withdrawal threshold or thermal withdrawal latency threshold of an 
un-injured hindlimb can be used to evaluate age- and dose-dependent anti-nociceptive analgesic 
effects. The efficacy of spinal analgesics has also been evaluated by nocisponsive behaviors to 
local irritants such as formalin 198 or mustard oil 199, and also in facilitated hyperalgesic states 
such as carrageenan-induced inflammation 188,190,196. 
 
In early life, an enhanced sensitivity to opioids is demonstrated whether given by systemic 200, 
epidural 189,201 or intrathecal 186,202 administration, and lower dose requirements with 
neuraxial administration confirm selective spinal analgesic effects 186. Changes in opioid 
receptor distribution in the dorsal root ganglion and spinal cord are likely to contribute, and may 
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also explain modality specific differences in efficacy against thermal and mechanical stimuli 
189,202–204. Lower doses of opioid 186,201, local anesthetic 188, NMDA antagonist196 and 
alpha2 agonist190,199,205 reverse injury-induced hyperalgesia and/or increase withdrawal 
thresholds in neonatal rat pups when the dose is adjusted for weight. 
 
Side effects 
Effects unrelated to analgesia may be usefully considered as those which are reversible and those 
that are irreversible. Side-effects such as sedation, motor impairment, and cardiovascular 
changes can often limit dose escalation. These dose-dependent effects can be evaluated in 
laboratory studies and compared with analgesic doses to determine the therapeutic window 
(difference between dose producing side-effects and the analgesic dose) at different ages. In 
humans, such side effects may represent: i) a spinal action (e.g. inhibition of the micturition reflex 
after spinal morphine)206; ii) a direct neuraxial redistribution to the brain (as with the behavioral 
disruption reported after intrathecal ziconotide) 207; or iii) systemic redistribution of the neuraxial 
dose after intrathecal delivery (e.g. rapid sedation after intrathecal lipophillic agents such as 
sufentanil) 208. Side-effect end points may vary with age. Thus, in preclinical models, in addition 
to lower anti-hyperalgesic dose requirements with epidural dexmedetomidine, the dose that 
significantly prolonged the righting reflex or reduced heart rate was lower in the youngest animals, 
resulting in a narrower therapeutic window in early life 190,199. It should be stressed that these 
side effects represent adverse events that are related to the physiological and reversible 
pharmacodynamic profile of the particular competitive agent. Support of function, such as 
respiration and blood pressure, until drug clearance or reversal will often prevent any further 
deterioration. These events are important as they limit the useful dose range of the agent that can 
be practically tested and to which the patient may be safely exposed. This would be defined as 
the maximum tolerable dose (MTD). 
 
In contrast, drugs at some concentration or dose exposure may exert a direct effect upon cellular 
function and lead to irreversible changes in cellular viability and thus represent tissue toxicity. 
Such end points would be, for example, expression of apoptosis or necrosis, frank demyelination, 
or changes in endothelial cell function. Some of these effects may be manifest by changes in 
spinally mediated behaviors or physiology, such as seizures, paralysis or anesthesia. On the other 
hand, where the tissue injury is delimited or where changes are slow and initiate compensatory 
actions, such effects may not be associated with functional or behavioral changes in the 
preclinical model. An example of this is the slowly growing, space occupying granuloma 209. 
Here, the appropriate criteria are the systematic post mortem assessments of target tissues 
(spinal cord, nerve and DRG). Without this, the absence of negative functional signs can be a 
false negative as regards tissue toxicity. 
 
Preclinical spinal drugs: developmental toxicity 
Impact of postnatal age 
 
Preclinical models for assessing intrathecal and epidural drug safety have been established in 
adult animals 210, but there has been little effort until recently to develop models for assessing 
spinal toxicity throughout the early postnatal period of development. It is crucial that while 
persistent changes in behavior after neuraxial drug treatment maybe a signature of direct tissue 
toxicity, absence of such changes cannot be construed as being an absence of toxicity. Such an 
assertion requires demonstration of absence of neuropathology, e.g. histological signs, increases 
in apoptosis, and alterations in glial response in exposed tissues. We argue that an important 
element in considering drugs for neuraxial delivery in human neonates and infants is their 
appropriate preclinical evaluation. In the following sections we will consider several variables that 
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we believe impact upon the preclinical assessment of developmental toxicity of neuraxially 
delivered agents. 
 
Activity-dependent neural development 
There are well-established critical periods in early postnatal life when the normal development of 
neuronal circuits is activity-dependent, and alterations in neural activity can produce long-term 
consequences that are not seen following the same perturbation in the adult 211. Neural activity 
promotes synaptic strengthening and network formation; whereas lack of activity and failure to 
form appropriate synaptic contacts can result in programmed cell death (apoptosis). In contrast 
to excitotoxic cell death, apoptosis is a normal developmental process for activity-dependent 
matching of pre and post-synaptic populations and the refinement of neural circuits. However, 
during these critical periods, exposure to drugs such as general anesthetics that reduce excitation 
(NMDA antagonists) or enhance inhibition (GABA agonists), may trigger excessive degrees of 
apoptosis in many brain areas 11,212–216. The degree and distribution of apoptosis change 
during the first 2 postnatal weeks, with peak susceptibility in the cortex around P7 217. Prolonged 
general anesthesia in P7 pups increases apoptosis not only in the brain but also in the spinal cord 
76,218. Changes outlined below also emphasize the significant plasticity of the developing cord. 
As such, neuraxially administered anesthetics and analgesics which alter neural activity in the 
cord may also produce specific patterns of toxicity that differ from those seen at older ages. 
 
Developing spinal cord structure and function 
During postnatal development there are significant structural and functional changes in 
nociceptive circuitry in the spinal cord. A-fiber afferent terminals initially project throughout the 
dorsal horn and only gradually withdraw to deeper laminae over the first 3 postnatal weeks in the 
rat as C-fiber projections mature 219,220. The normal postnatal development of A- and C-fiber 
innervation in the spinal cord is activity-dependent and can be altered by changing input at critical 
stages 221. Blockade of synaptic activity by a neuraxially administered slow-release NMDA 
antagonist prevents the structural re-organization of A-fiber terminals and the neonatal pattern of 
low mechanical withdrawal thresholds and large dorsal horn receptive fields persists into 
adulthood 222. The somatotopic organization of primary afferent terminal fields can also be 
altered by changing neural input during the neonatal period 223,224. Cell death in the DRG is a 
normal developmental phenomenon and is balanced by proliferation in early life 225. However, 
cell death occurs more rapidly and to a greater extent after sciatic nerve section in neonatal 
compared with adult animals 226. Importantly, responses to neonatal injury such as inflammation 
or surgical injury have been associated with long term functional consequences and an enhanced 
sensitivity to future injury 197,227–230. 
 
The balance between excitatory and inhibitory activity in the spinal cord changes during the 
postnatal period197,231–233. Excitatory glutamate receptors (AMPA, NMDA and metabotropic 
glutamate receptors) are highly expressed and tend to be more widely distributed in the neonatal 
spinal cord. Developmental changes in subunit expression of the NMDA receptor are associated 
with changes in channel kinetics and increased calcium influx that further increase excitatory 
effects231,232, and may influence the potential for toxicity. GABA inhibition is functional at a 
cellular level, but there is minimal glycine-mediated inhibition in the neonatal spinal cord 234 and 
a delay in the overall maturation of inhibitory networks194,233,235,236, and local GABA-
mediated inhibition in the cord is initially dominated by descending excitatory effects237,238. 
Ketamine and propofol have been shown to increase cell death and alter dendritic arborization of 
GABAergic neurons in vitro239,240 but effects in spinal networks have not been directly 
evaluated. 
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Standards for preclinical evaluation of efficacy and toxicity of spinal analgesics 
Characteristics of preclinical safety evaluations 
Preclinical safety evaluations by definition employ surrogate models with key characteristics that 
mirror those of the human condition; in this case, the mammalian neonate during the early post 
natal phases of development receiving spinal drug exposure in a validated model. As reviewed 
above, the minimal component to an appropriate assessment of toxicity is the systematic 
consideration of pathology in the neuraxis as compared to the appropriate neuraxial vehicle 
control. 
Validated model and drug delivery 
To date the principal developmental toxicity model employed for neuraxial delivery has been 
percutaneous delivery in rat pup; but the model (i.e. the animals and the delivery system) must 
be validated. This implies that the drug delivery has been reliably demonstrated to occur within 
the intrathecal space (an important issue where the delivery has been percutaneous puncture) 
and that the injection protocol (needle placement, volume) results in an adequate and reliable 
distribution of the injectate. As discussed earlier, preliminary studies are required to ensure 
reliability of the technique in the hands of each investigator, and to avoid confounding effects of 
dyes in toxicity studies correct placement can be confirmed by measuring a predetermined 
dose-dependent acute behavioral change (eg. increase in hindlimb withdrawal threshold or 
motor block). In addition, the model should have the ability and sufficient sensitivity to reveal a 
profile of toxicity that has been previously described (e.g. apoptosis or demyelination). 
It is of fundamental importance that appropriate control groups are included to statistically 
differentiate between the effects of the interventions and effects of the intervention plus drug. A 
saline injection group will demonstrate effects related to the technique, needle trauma or volume 
of injectate. In addition, comparison with a naïve group ensures effects are not related to the brief 
anesthesia, handling or maternal separation required for the procedure 186. 
 
Spinal toxicity in adult models has been evaluated following both epidural and intrathecal delivery. 
Although both intrathecal and epidural delivery have been demonstrated in the neonatal rat, 
current toxicity models focus on intrathecal delivery. Higher doses or concentrations of epidural 
drug are frequently required to achieve similar concentrations at target sites within the spinal cord. 
As such, the worst-case scenario is the intrathecal delivery of an intended epidural agent; not only 
because of the risk of increased acute side-effects, but also because of the exposure of the cord 
to an increased dose or concentration of drug. Cases of unrecognized dural puncture and 
inadvertent total spinal have been reported in large series (2 per 10,633 cases35 and 1 per 
10,09817). In addition, the overall incidence of dural taps has been reported at 0.12% 16 and 
0.1% (CI 95% = 0.05–0.19)17, and 6 of the ten dural taps in the latter survey were associated 
with caudals in babies. This further emphasizes the need to establish a safety profile for all 
neuraxial drugs, whether epidural or intrathecal delivery is planned. 
Animal age 
The infant rodent is frequently utilized as a model for evaluating the progress of postnatal 
mammalian development. While direct translation of different developmental ages from rodents 
to humans, and the specific timing of events after birth, continues to be debated, the sequence 
of development of sensory and reflex systems in rodents correlate with those of human infants 
241. Statistical models have been developed to translate development across species 242,243, 
but are predominantly based on structural measures, and acknowledge that as peak 
synaptogenesis is more complex and more prolonged in the human, the model can not account 
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for activity-dependent modification following birth 244. In terms of spinal processing many 
approximate a P3 rat with a preterm human neonate, P7 with an infant, P21 with an adolescent, 
and P35 with young adulthood 197,245,246. Translational developmental models based on 
correlating behavioral measures support these estimates 241. In both humans and rats, 
locomotor capabilities develop postnatally, with a gradual rostrocaudal pattern of maturation. 
Rat pups ambulate through use of forelimbs and the upper torso by P3-4, crawling behavior 
peaks around P7, body weight is fully supported by P12-13, and rearing without foreleg support 
is achieved by P18 241. Spinal reflexes, which incorporate both sensory and motor 
development, also show similarities in the sequence of development in the postnatal rat and 
human infant 247,248, with gradual maturation from low threshold 190,249–251, large receptive 
fields 251,252, poorly directed and generalized responses 250,251,253 in both rodent and 
human infant early life. Clear relationships between the intensity of the stimulus and the degree 
of reflex withdrawal response 229,254,255 are maintained at all ages, thus facilitating evaluation 
of the response to injury and/or analgesia. 
 
Vulnerability to apoptosis in the brain coincides with rapid synaptogenesis or the brain growth 
spurt, which occurs predominantly in the first two postnatal weeks in the rodent, but may extend 
from mid-gestation to several years after birth in the human infant 216. The majority of 
preclinical studies evaluating general anesthetic effects in the brain have focused on P7 as 
apoptosis peaks in the cortex at this age, and drug effects are most apparent in regions where 
spontaneous apoptosis is occurring 217,256. Spontaneous apoptosis occurs in the postnatal 
spinal cord, occurs predominantly in the dorsal horn, and peaks at a slightly earlier 
developmental stage than seen in the cortex with the number of apoptotic cells highest at P2-
P5, and decreasing by P8-10 196,257–259. As peak apoptosis occurs at an earlier age in the 
spinal cord (P3 rather than P7) than the cortex, the period of susceptibility to pro-apoptotic 
drugs may be shorter, but prolonged general anesthesia does increase apoptosis in the cord at 
P7 76,218. In addition, as there are ongoing changes in the structure, function and synaptic 
connectivity of neural networks in the spinal cord throughout the first 3 postnatal weeks 232, 
assessment of developmental neuraxial toxicity should include a range of ages. This also 
addresses the potential uncertainty in the precise parallels between the postnatal development 
in the human and rodent. 
Evaluation and Outcomes 
This review will not seek to cover the appropriate histopathology in detail, but experts in the fields 
of neuropathology will argue that to define the absence of pathology, one must satisfactorily 
address a number of specific issues and tissue targets. 
 
Blinded assessments 
Evaluation must include an analysis that is made independent of knowledge of tissue/animal 
treatment, with groups that at a minimum include vehicle vs drug treatment cohorts with tissue 
harvested at predetermined intervals after drug exposure. 
 
Histopathology 
Analysis of pathology requires appropriate selection of histopathologial targets and indices. 
 
i. At the minimum, it is reasonable to systematically examine hematoxylin and eosin sections 
to note necrosis, gliosis, and inflammation. Such examination typically includes spinal cord 
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and meninges, may also include dorsal root ganglia, and evaluation of nerve roots and 
demyelination is particularly relevant for assessing effects of local anesthetics 260,261. 
ii. Evaluation of apoptosis and neuronal cell death is an important additional component in 
early development. Although a range of potential techniques are available 262, activated 
caspase-3, an enzyme in the apoptotic cascade which marks neurons progressing beyond 
the point of commitment to cell death 263 has been frequently used to identify apoptosis 
in the brain and also the spinal cord 76,186,196,218. Fluorojade C is an additional marker 
of neuronal degeneration 264, and we found a pattern of staining that correlated with 
activated caspase-3 immunohistochemistry 186,196. 
iii. Activation of non-neuronal cells by the use of specific astrocyte (GFAP) and microglia 
(IBA1 or OX42) markers can provide further indicators of altered function and the response 
to injury. 
iv. Evaluation of potential nerve injury requires assessment of the state of myelination. 
Previous work has shown that local anesthetics can produce signs of demyelination of the 
cauda equina 265,266. As myelin is in the developing stage up through postnatal day 3, 
acute effects on myelin may be difficult to assess. Others have focused on apparent 
changes in the root at later time points, or in the dorsal column which represents the 
ascending collaterals of large primary afferents 76. 
v. As mechanisms associated with developmental anesthetic toxicity are further clarified, 
additional factors requiring evaluation in the developing spinal cord may be identified. As 
noted earlier, ketamine and propofol have effects on the dendritic tree of cultured cortical 
and hippocampal neurons.240,267,268 As changes in dendritic morphology in the spinal 
cord have been noted in developmental neurological disorders and have a role in synaptic 
plasticity after nerve injury,269,270 similar mechanisms may be relevant for 
developmental toxicity in the spinal cord. Neurotrophic factors and actin depolymerization 
have been associated with apoptosis in cultured neuronal cells exposed to propofol271 
and isoflurane,272 but effects in vivo273 and relevance to analgesic toxicity in the spinal 
cord has not yet been established. 
vi. A corollary to this commentary is that evaluation of the potential for spinal toxicity must 
involve the use of in-vivo animal models. Such models may be complemented by the study 
of drug effects in ex-vivo or in-vitro models, as has been widely employed to study local 
anesthetic toxicity. Changes in DRG cell function, or clonal cell viability or ex-vivo nerve 
exposure274–277 all provide important approaches to define potential mechanisms. 
However, as useful as the ex-vivo system is for characterizing local drug effects, care must 
be taken in extrapolating these results to the intact organism, as they can just as easily 
provide false positive indications which may not be relevant to in-vivo safety or pathology 
related to a given drug (see278). 
 
 
Age at time of exposure 
An important issue relates to the developmental age at initial drug exposure. As reviewed above, 
critical postnatal periods of neural development are represented by the onset of innervation, 
development of myelination of the long tract and primary afferents, and the time course of 
spontaneous apoptosis. On this basis, we have argued that appropriate ages in the rat are P3, 
P7 and P21, with P21 reflecting an animal that has essentially reached a steady state for the end 
points indicated 
 
Survival time post exposure 
Initiation of cell death may begin as early as 6 hours after toxin (drug) exposure, and caspase-3 
immunoreactivity may be reduced at later time points as the cell decomposes 263. In the spinal 
cord, we found increased apoptosis 6 hours following intrathecal ketamine at P3, and significant 
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increases were maintained at 24 hours 196. However, glial reactions and evidence of 
demyelination may not be maximal until a later time point 76,196,261,266. Accordingly, an optimal 
characterization would include both an early (6–24 hrs) and later interval (7 day) of post treatment 
recovery. Longer-term effects on functional outcomes must also be considered, and be sufficiently 
sensitive to detect changes that are related to any observed structural or histological defects. For 
example, as general anesthetics at P7 increase apoptosis in the hippocampus, long-term effects 
on learning and memory have been evaluated 10. Although prolonged general anesthesia 
increased apoptosis in the spinal cord, motor performance on the Rota-rod at P30 was not altered 
76,218. Whereas local anesthetic toxicity or demyelination may result in changes in motor 
function, spontaneous apoptosis in the ventral horn occurs mainly before birth 257. Spontaneous 
apoptosis 257,259 and increases following intrathecal ketamine at P3 occur predominantly in the 
dorsal horn, with associated long-term changes in mechanical thresholds for hindlimb withdrawal, 
and in static but not dynamic parameters of gait 196. This suggests that alterations in sensory 
and motor function should be included when evaluating long-term effects of neuraxial drugs. 
 
Drug exposure and dose 
To have credibility as a robust assessment paradigm, the drug exposure must occur at neuraxial 
doses which by the metric of concentration and dose equal or exceed those destined for the 
human condition. One limitation of percutaneous administration is that effects of dose are limited 
to single administrations rather than ongoing infusion and chronic exposure. Intrathecal 
catheterization has been reported in pups as young as P3, but motor deficits and histological 
damage have been noted ipsilateral to the catheter 187, thus limiting the utility of this method for 
assessing toxicity. The use of a single dose runs the evident risk that a drug will be observed to 
have pathology at a dose which is well beyond any reasonable clinical exposure. Nevertheless 
the higher the dose examined without pathology the more confident we can feel that the assertion 
of “no toxicity” is valid 173. 
 
Translation of drug exposure and dose 
An important question relates to the expression of the dosing, and the translation of dosing in the 
surrogate to the target species. After systemic delivery the typical metric for dose response is the 
body mass (eg. mg/kg). However, it is widely appreciated that across large ranges of body weight, 
a more appropriate metric may be body surface area, particularly when precise dosing is required 
to maximize the therapeutic response while minimizing the likelihood of unacceptable toxicity (e.g. 
chemotherapy dosing)279 (Table 3). As BSA has also been shown to correlate across 
mammalian species with physiological functions (such as metabolic rate, blood volume and renal 
function), BSA rather than body weight has been used when converting doses across species to 
humans. The Km factor (body weight in kg divided by BSA in m2) is often incorporated in formulae 
for species conversions: e.g. human equivalent dose (HED, mg/kg) = animal dose (mg/kg) × 
[animal Km/human Km]280. Such calculations aim to produce a comparator that generates a 
proportional plasma level and are important for converting no adverse effect levels (NOAELs) 
established in preclinical studies to doses used in clinical trials 281. However, the FDA also 
acknowledges that this approach has limited applicability when drugs are administered into 
anatomical compartments, such as the intrathecal space, where there is little subsequent 
distribution and where there may be as much as two fold difference in local volume 282. 
Considering the spinal dose in terms of mg/kg in two adult humans that may differ by a factor of 
two in body mass may be appropriate for avoiding systemic toxicity or side-effects associated with 
redistribution or inadvertent injection into vascular structures. However, variability in intrathecal 
volume is likely to be less, and as toxicity may be more dependent upon the compartmental 
volume (i.e. cerebrospinal fluid volume and/or its turn over) it is the local concentrations to which 
the tissue is exposed that is important 281. The problem is yet more complicated where one 
compares across species, and different methods for dose conversion are shown in Table 3. When 
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expressed as age-specific concentrations (total dose in mcg per mcl CSF volume), analgesia is 
achieved at twice the concentration of morphine and 42 times the concentration of ketamine and 
clonidine in neonatal pups. The maximum tolerated doses of intrathecal morphine 186 and 
clonidine 205 did not produce toxicity in the rat, despite being delivered in concentrations 
approximating 600 or greater than 10,000 times respectively than concentration required for 
clinical analgesia. By contrast, intrathecal ketamine196 produced toxicity at <150 times the clinical 
concentration. Although these conversions require some assumptions, and are approximate as 
only limited dose intervals were assessed, they provide comparisons of different agents, and 
again demonstrate the reduced safety margin of ketamine when compared to morphine and 
clonidine. 
 
The therapeutic ratio of toxic to analgesic dose: a way forward? 
The relative efficacy and safety of different treatments, and the potential benefits and risks for 
individual patients, are essential for choosing the most appropriate drug in clinical practice. Safety 
studies frequently appreciate that every agent examined neuraxially will at some point display 
pathology. The issue is that the drug must have a therapeutic dose that is lower than the dose 
that produces untoward effects upon behavior or exerts direct tissue toxic ity. Ideally, this 
therapeutic window is wide, but depending on the desired outcome a narrower margin may be 
tolerated. For example, chemotherapeutic agents produce significant side-effects and toxicity, but 
the potential benefit for the patient is deemed to outweigh this risk. Similarly, despite concerns 
about pro-apoptotic effects of general anesthetics, it is clearly not appropriate to withhold 
anesthesia for neonates requiring surgery. However, if several agents produce a similar 
therapeutic end point (e.g. analgesia) what algorithm might we use to select the one least likely 
to have a deleterious action? One strategy is to define the therapeutic ratio of the several agents 
under identical conditions. In this case, one notes the quotient of the minimum dose without tissue 
toxicity and the minimum dose required to produce a therapeutic effect of the intrathecally 
delivered agent. In recent studies we showed that the therapeutic ratio in early life was > 300 for 
morphine and clonidine, but < 1 for ketamine as increased apoptosis occurred in the same dose 
range as analgesia 186,196,205. While the ratio can vary for different reasons across end points 
and laboratories, we would argue that in a given assessment paradigm, if two drugs have similar 
analgesic efficacy, but differ in their therapeutic ratio, the agent with the higher therapeutic ratio 
will be preferred, all other things being equal. 
 
This particular strategy provides a rationale in the current environment to minimize the potential 
complications secondary to direct tissue toxicity, particularly where old drugs are being given by 
a new route (e.g. neuraxial) or where new drugs or preparations are being considered for 
neuraxial use. As noted above, with ongoing clinical use, it can become apparent that even 
commonly employed agents may lead to pathology; as seen following intrathecal infusion of local 
anesthetics 283 and chronic intrathecal morphine 284,285. 
 
Conclusion 
We acknowledge that neuraxial anesthesia is an important component of perioperative pain 
management in children of all ages, and particularly in neonates and infants as inadequately 
controlled pain in early development may also have adverse long-term effects 197. Our aim is not 
to discourage use of neuraxial anesthesia, but rather to encourage use of agents with 
demonstrated efficacy and the widest possible safety margin. Clinical studies are well suited to 
assessing tolerability and efficacy, but cannot reliably confirm safety and an absence of 
morphological effects136. Therefore, we complete this overview of neonatal neuraxial analgesic 
utilization by emphasizing four points. 
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First, we believe it is evident that the potential for spinal drug toxicity may present a greater 
problem in early life because of the dynamic properties intrinsic to neuraxial development. 
 
Secondly, given the above issues, we believe that advances in this area require systematic 
preclinical assessments of the comparative safety of candidate agents with attention being paid 
to the therapeutic ratio of the neuraxially delivered agent, the developmental time of exposure to 
the agent, and assessment of neuropathology (apoptosis, myelination, gliosis and dendritic 
morphology) and long term functional outcomes. Further, the research must recognize that the 
critical periods of development that occur (e.g synaptogenesis, myelination and apotosis) differ 
for brain and spinal cord. Of equal importance, as the algorithm relating rodent and human 
neonatal development cannot be precisely matched, preclinical safety evaluations must review a 
range of developmental ages in their respective models. 
 
Thirdly, there is a need for a greater appreciation by institutional review boards regulating clinical 
trials, and by editors and reviewers of scientific publications, of the issues of potential toxicity and 
the degree to which the clinician-investigator has adequately addressed these concerns. 
 
Finally, we must entertain a high index of suspicion of potential toxicity when drugs are 
administered neuraxially. As children are rarely subject to detailed assessment after day-stay 
surgery, there is the potential to under-estimate the rate of complications67. This is particularly 
important in neonates and infants, who may not only be more susceptible to perturbations in 
neural development, but who are also unable to report sensory symptoms and as they are not 
walking, subtle motor deficits may be missed. We agree with others, that more thorough follow-
up of children following neuraxial analgesia is required68, with longer-term epidemiological 
studies to establish clinical safety286. Integrating preclinical and clinical data has also been the 
focus of studies evaluating adverse neurodevelopmental outcomes following general anesthetic 
exposure in early life. In this situation, the clinical benefits of diagnostic investigations and surgery 
with adequate anesthesia outweigh the risks identified in laboratory studies, and although 
modifications in practice have been suggested287, current data do not support significant 
changes in clinical practice or provide clear evidence of a better alternative11,215. However, 
when considering the choice of spinal analgesic adjuvants, many provide similar analgesia but 
not all have undergone systematic evaluations of spinal toxicity, and changing practice to include 
only agents with the widest demonstrable safety margin can be achieved without compromising 
clinical care. It is essential to ensure that every step is taken to evaluate both the benefits and the 
safety of new and existing spinal drugs, prior to routine clinical use, to minimize the risk of an 
unexpected and untoward outcome. 
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Table 1 Spinally-administered Local Anesthetics in Neonates and Infants. 
 Route Concentration/Dose Age Design / sample Outcome / Results Side-effects/ 
Complications 
Ref 
Bupiv acaine IT 0.5mg/kg 0.5% = 0.1ml/kg 
(<5kg); 0.4mg/kg (>5kg) 
< 1mth n=20; 1- 
3mths n=26; 3- 
6 mths n=22 
Case series; inguinal 
hernia repair 
In youngest: higher proportion (95%) 
withadequate spinal but less postop 
analgesia 
Mild hypotension 288 
 IT Hyperbaric 0.5% 1mg/kg + 
epinephrine 
Birth 24-40wks;  
postnatal age 5- 
24wks, n=20 
Case series: 17 
inguinal hernia, 2 
stoma, 1 teratoma; 
BIS monitoring 
100% successful block; decrease BIS 
values 15 mins post spinal  
>20% decrease in 
BP; HR stable 
289 
 IT Isobaric 0.5% bupi vs 
hyperbaric 0.5%bupi in 
8%glucose;0.5mg/kg 
<10kg, 0 .4 m g/kg  11-
1 9 kg ,  0.3mg/kg >20kg 
2-115 mths, n=100 DB, randomized; lower 
abdo and lwr l imb 
Success (complete sensory block) 
higher with hyperbaric (95% vs 82%); 
n o  d if ference in height  of se nso ry 
block (but wide variabil ity both 
groups), degree motor block or postop 
analgesia 
Treatment required: 
10 suppt O2; 1 
hypotension; 1 
bradycardia 
290 
 IT Isobaric 0.5%; mean dose 
0.68±0.16mg/kg 
Gestational age at 
operation: 47.6 (28- 
1 20) wks; 
n=505 
Case series: lwr abdo, 
perineal, lwr l imb (79% 
ing hernia) 
Successful spinal 96%; 
conversion to GA 1%(surgery 
>90mins); sedation required 28% 
Ave. spinal tap 
attempts 1.4 (1-6); 
bloody tap 12.4%; 
Bradycardia 1.8% 
(6/9 require 
atropine); High block 
3pts (2 req. 
intubation) 
19 
 IT + EP- 
B (C) 
Isobaric 0.5% 1mg/kg IT in 
spinal grp; 
All: plus caudal 0.25% 
2mg/kg 
40 (36-44) wks PCA; 
n=10 
(n=14 GA 
sevoflurane) 
RCT: spinal vs GA Successful spinal 72%; 
decreased postop cardiorespiratory 
events in spinal grp 
Unsuccessful spinal 
28% (4/14) 
291 
 IT (CSE) IT:isobaric 1mg/kg 0.5% 
Caudal catheter 
(advanced to 
thoracic):0.2mg/kg/hr 
0.1% 
31-53 wks PCA, 
n=28 
Case series; CSE sole 
te ch n ique fo r major 
upr abdo surgery 
Satisfactory surgical anesthesia in 
24/28 (4 convert to GA); 20 
supplemental midazolam; 
Multiple spinal 
attempts 3/24; 
CVS parameters 
stable 
24 
 EP-
B(L) 
Iml/kg 0.25% 
bupi+epinephrine then 1 
ml/kg 0.125% every 2 hrs 
intra-operatively 
36-41 wks PCA 
repair on 4th±5 days 
(1-23dys) 
n=23 
Case series: bladder 
exstrophy repair 
Intraoperative bupivacaine bolus 
(postop lidocaine; see below). 7/23 
required intraop fentanyl. 
 37 
Ropiv acaine IT 1.08mg/kg 0.5% = 
0.216ml/kg (ED95) 
<55 wks PMA n=50 Dose finding, inguinal 
hernia 
Effective; motor block shorter duration 
and variable (cf other agents) 
 292 
 EP-B 
EP-I 
0.9-2mg/kg 0.2% (L)+ 
0.2mg/kg/hr 0.2% 
(<6mths); 0.4mg/kg/hr 
(>6mths) 
0-1mth, n=11; 1- 
3mths , n=10; 3- 
6 mths , n=10; 6- 
1 2 mths, n=14 
Case series; major 
abdo/thoracic surgery 
Decreased clearance in neonates; 
Unbound plasma concentration higher 
in neonates 
 293 
 EP-I 0.2% 0-2ml/kg/hr Neonate; n=22 Case 
series;gastro
schisis 
Decreased postop ventilation in 
regional vs opioid 
 38 
 
 
38 
 EP-
B(C) 
1ml/kg 0.2% 0-12mths, n=10; 1- 
5yrs, n=10 
Pharmacokinetic 
study; inguinal hernia 
repair 
Higher plasma concentration in infants No signs systemic 
toxicity 
294 
Lev o-
bupiv acaine  
IT 0.5 to 1.2 mg/kg 0.5% < 55 wks PCA; n=50 Dose finding, lower 
abd surgery 
Recommended dose 1mg/kg No significant 
adverse effects 
295 
 EP-
B(C) 
2 mg/kg 0.25% 2±0.7 (0.6-2.9) 
months; n=22 
Pharmacokinetic 
study; lwr abdo 
surgery (82% inguinal 
hernia) 
Decreased clearance in infants  296 
Lidocaine EP-I 0.8-1mg/kg/hr 0.1% 
postoperative infusion 
36-41 wks PCA 
repair on 4th±5 days 
(1-23dys) 
n=23 
Case series: bladder 
exstrophy repair 
*Duration: 15±8 days 
(4-30days) 
Adjust infusion to maintain plasma 
concentration <5mg/L; 22/23 required 
reduction in infusion in first 48hrs. 
Tunneled catheter: 10/23 early 
dislodgement at 13±7 (6-28) days 
 37  
Tetracaine IT Lidocaine 3mg/kg + 
epinephrine 
Tetracaine 0.4mg/kg or 
0.4mg/kg + epinephrine 
1mth -12 mths 
(7/100 < 44 wks 
PCA; 77/100 < 
6mths); 
n=100 
Case series: lwr abd, 
lwr l imb (87% inguinal 
hernia) 
Duration motor block: 
l ido + epin 56±2.5 mins 
tetracaine 86±4mins 
tetracaine + epin 128±3mins. 
Sedation: methohexital 78; ketamine 
4) 
Four or less spinal  
tap attempts; no 
bloody taps. 
CVS stable. 
Follow-up 7-10days: 
no complications 
297 
 IT/ CSE Mean dose 0.65mg/kg 
Post-op caudal catheter: 
bupivacaine 0.25mg/kg/hr 
(neonates) or 0.5mg/kg/hr 
(infants) 
29wks PCA to 7 
months; 1.5-7.8kg; 
n=19 
Case series; major 
abdo surgery 
+ CSE bupi via caudal cath Sedation 7/19 (1 
propofol, 6 
midazolam); 
Subarachnoid block 
with catheter 1 
(required intubation) 
23 
 IT Mean dose 0.56 mg/kg 
0.5% in dextrose 5% 
Neonates, n=14 Case series:repair 
meningomyelocele 
Additional doses by surgeon Postop apnea in 2 
with midazolam 
sedation 
298 
 IT 1ml/kg 0.5% tetracaine (or 
0.5% bupi) + 5% glucose  
+ adrenaline 
24-42 wks gest age, 
n=62 
Case series; 58 ing 
hernia, 3 
pyloromyotomy, 1 
muscle Bx 
Spinal success 89%; 5.4% req GA; apnea 
3%; bradycardia 4% 
299 
 IT 0.5ml/kg 0.5% tetracaine + 
5% dextrose + epinephrine 
24-37 wks gest age, 
n=142 
Case series: 95% 
inguinal hernia; 5% 
urology 
Spinal success 96%; 4.5% sedation; 
apnea 0.8%; brady 
1.5% 
44 
 IT Hyperbaric; mean dose 
0.54±0.2mg/kg 
(+epinephrine in 91% 
(excluding PDA); 
[0.4% cases: hyperbaric 
bupi or l idocaine] 
Neonates and 
infants (<12 
mths):650g-13kg; 
n=1554 
Case series: abdo, lwr 
abdo and lwr l imb; 
urology; 
myelomeningocoele; 
(55% ing hernia) 
Spinal adequate for surgery 
95%;supplemental LA by surgeon 
2.7%; 
1.4  conversion to 
GA(su rg ery 
duration > block); 
bradycardia 1.6% 
(15/24 require 
treatment); sedation 
24%; SaO2 <90% 
0.6%; high block 56 
patients (5 assist 
ventilation, 5 
13 
 
 
 
 
 
39 
      intubated)  
 IT Hyperbaric 0.5% in 5% 
dextrose + epinephrine ; 
Mean dose 2.4mg/kg 
Neonates mean 
PCA 33 (28 -
41)weeks; 1276 
(650- 2965)g 
n=14 
Case series, PDA 
repair 
Intubated and high dose to aim for 
total spinal; CVS stable; 
Supplement 7/14 
(isoflurane, 
midazolam, N2O or 
fentanyl); 
Decrease BP & HR 
1/14 
40  
Chloro-
procaine 
EP-
B+I(C) 
1ml/kg 3% ± 0.3ml/kg 
bolus to establish 
+ 1ml/kg/hr 
Ex-preterm 35-49 
wks PCA; n=10 
Case series; feasibil ity 
in awake, inguinal  
hernia (sole) 
Mean cumulative requirement 2.8±1 
ml/kg/hr 
BP mild decrease; 
one apnea (pre- 
existing episodes) 
28 
 EP-B+I 
(C) 
1-1.5ml/kg 3% bolus + 1- 
1 .5 ml/kg/hr 
Neonates, 1-28 
days; 2.2-4.9kg; 
n=25 
Case series, major 
abdo surgery (GA 
suppt) 
CVS stable 
st 
Caudal space on 1 
or 2nd attempt; 
CVS stable 
29 
 
Legend: IT: intrathecal; EP-B: epidural bolus administration; EP -I: epidural infusion; (L): lumbar injection; (L/T): lumbar or thoracic insertion/injection; (C): caudal injection; n.s. not 
statistically significant 
NB: studies with LA combined with opioid or adjuvant reported in Table 2 
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Table 2 Spinally-administered Analgesics in Neonates and Infants ( 6 months) 
 Route Concentration/Dose Age Design / sample Outcome / Results Complications Ref 
Opioids        
Morphine IT catheter 20mcg/kg bolus + 
3mcg/kg/hr postop (with 
0.1ml/hr 0.125% bupiv) 
2-11 mths; cardiac 
surgery with CPB; 
n=30 (spinal grp) 
RCT: spinal vs 
systemic opioid 
Decreased stress response in 
spinal group; no difference in time 
to extubation 
CVS stable; no spinal 
complications 
22 
 IT 7mcg/kg (with 2mg/kg 
tetracaine) 
3mths -6yrs, n=20 
spinal group 
RCT:spinal vs 
systemic opioid 
Lower pain scores and decreased 
postop fentanyl requirement (no 
diff in opioid side-effects) 
CVS stable 25 
 EP-B (C) 100mcg/kg (with bupi 
0.25% 1ml/kg + 
epinephrine 1:200000) 
3 – 56 mths; n=63 
(31/32 per grp) 
RCT: pre-incision 
caudal vs postop IV 
opioid; cardiac surgery 
(single ventricle 
palliation) 
No difference in extubation rates; 
postop morphine reqt n.s.; 
No adverse events 
specifically related to 
caudal 
45 
Hydro-
morphone 
EP-B+I 5-10mcg/kg + 0.6-1.5 
mcg/kg/hr 
n=220 (57 infants 
<12 months) 
C se series cardiac 
surgery (range of 
drugs and techniques; 
not clear if all used in 
infants) 
Regional safe and effective in 
cardiac surgery 
Intravascular puncture 1; 
paraesthesia 7 (?age); 
no identifiable spinal 
hematoma on postop 
neurological 
examination 
300 
Dia-
morphine 
EP-B (C) 30mcg/kg plus bupi 0.25% 
0.5ml/kg VS bupi alone 
6–88 months; 
n=45 
RCT; hypospadius 
repair 
Reduced pain scores first 30mins 
postop 
Minor decrease RR at 
15mins; PONV n.s. 
difference (3/22 vs 1/23) 
120 
Fentanyl EP-I Bolus 2mcg/kg + 
0.21mcg/kg/hr 
(+0.2mcg/kg/hr 
bupivacaine) 
12 days -18 years 
n= 348 (87 <2yrs) 
Case series; 80% 
orthopaedic 
Effective analgesia Cardiorespiratory stable; 
b a ck p a in at p uncture 
site 1 (?age); fever and 
catheter removal 11 (tip 
culture all negative); 
m e ch anical problems 
and early cessation 25; 
urinary retention (without 
routine catheter) 17% 
301 
 EP-B+I (L) 1-2 mcg/kg bolus + 
0.2mcg/kg/hr (plus 
bupivacaine 0.25% with 
epinephrine (up to 
0.8ml/kg bolus) + 0.1% 
0.2ml/kg/hr for mean 45 
(39-69) hrs 
Neonates; n=14 Case series, major 
abdo surgery; mean 
duration 43.7±8 hrs 
Satisfactory analgesia in all  Dural puncture 1/14 30 
 IT 0.25, 0.5 or 1mcg/kg (plus 
0.5% hyperbaric 
bupivacaine) 
Infants, mean 6-
7months; n=42 
RCT; lwr abdo and 
urology 
Addition 1mcg/kg fentanyl  
prolonged duration of SA block 
(74±6 vs 51±5 mins) and reduced 
postop rescue analgesia; 
0.25 and 0.5mcg/kg not different 
from bupi alone 
All low dose propofol 
infusion, ceased in 4 as 
required assisted 
ventilation; pruritus 3/42 
302 
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Clonidine IT 1mcg/kg clonidine plus 
hyperbaric bupi 0.5mg/kg 
VS 
1mcg/kg fentanyl plus bupi 
VS 1mcg/kg clon plus fent 
plus bupi VS bupi alone 
Infants 2-11 months 
(ex-preterm 
excluded); 
n=61 (15-16 per grp) 
RCT DB; lwr abdo 
surgery under SA 
block (80% inguinal 
hernia) 
Sensory block height T4-T8 Sedation score higher 
and intraop propofol 
requirement lower in BC 
& BCF grps; CVS stable 
303 
 IT 0.25, 0.5, 1 or 2mcg/kg 
(plus 0.5% isobaric bupi 
1mg/kg) 
38-46 wks PCA, 
n=75 
RCT; inguinal hernia Duration incr by 1 & 2mcg/kg; 
recommend 1mcg/kg 
MAP decr by 22-40% 
(higher proportion 
MAP<40mmHg in C2); 
HR decr 12-27% all 
groups; no diff early 
apnea **limited follow-up 
until PACU discharge 
26 
 IT 1mcg/kg (plus 0.5% 
isobaric bupi 1mg/kg) 
Prem vs term (29- 
50wks vs 39-53wks 
current PCA), 
n=67+57 = 124 
Prospective 
observational; inguinal 
hernia 
Success rate 84% Unsuccessful block 10; 
inadequate duration 13; 
high block and resp 
impairment 1. 
Incr proportion apnea 
postop (6 before surg, 
26 in 24hrs post 
surgery); increased 
bradycardia postop 7; 
"deeply sedated" 5 
27 
 EP-I (L/T) Bolus 2mcg/kg + 
0.2mcg/kg/hr OR 
0.2mcg/kg/hr plus 
ropivacaine 0.1% 
(0.2mls/kg/hr) 
3 - 98 months; n=35 Randomised, non 
blinded; major abdo 
surgery 
"good analgesia" in both groups;; 
rescue analgesia required for 
cough and movement 
Clonidine bolus 
increased sedation and 
hypotension; HR and 
RR stable 
132 
Ketamine EP-B (C) s-ketamine 1mg/kg ± 1 or 
2mcg/kg clonidine 
(3groups) 
1-72 mths (mean 
26±24mths) 
RCT; inguinal hernia K+C longer duration; suppt 
analgesia in 24hrs: 63% vs 16% 
with combination (paracetamol? 
single dose) 
CVS stable; “no adverse 
CNS effects” (?criteria); 
24 hr follow-up 
98 
 EP-B (C) s-ket 0.5mg/kg ± 1ml/kg 
levobupi 0.15% or 0.175% 
or 0.2% 
3 mths - 6 yrs 
(mean 3 yrs), 
n=164 (52-56 per 
grp) 
RCT D-B; lwr abdo or 
urology (57% inguinal 
hernia) 
Adequate analgesia on incision 
162/164 
0.175% + K: lwr analgesic reqt 
(22/52 vs 38/56 vs 30/56) 
Postop agitation 34/164; 
no ‘excess agitation or 
odd behavior’; 6hrs 
postop follow-up 
97 
 EP-B (C) Bupi 0.125% 0.2ml/kg ± s- 
ketam i ne 0.5mg/kg 
1 mth -9yrs (mean 
2.7yrs), n=30 
RCT D-B;lwr abdo or 
urology (60% inguinal 
hernia) 
10/15 in ket grp vs 3/15 no 
additional analgesia 
CVS stable, no 
emergence delerium or 
unexplained distress 
137 
 EP-B (C) s-ketamine 0.5mg/kg vs 
1mg/kg vs bupi0.25% 
0.75ml/kg with epinephrine 
3 mths -6 yrs; n=49 RCT D-B; inguinal 
hernia repair 
ket 1mg/kg = LA > 0.5mg/kg; 33 vs 
30 vs 72% suppt paracetamol  
CVS stable; no 
difference in sedation; 
no motor block at 6hrs 
144 
 EP-B (C) 0.25 or 0.5 or 1mg/kg plus 
bupi 0.25% 0.75mls/kg 
6 mths –10 yrs; 
n=60 
RCT; unilateral  
inguinal hernia 
0.5 and 1mg/kg prolonged 
analgesia and reduced rescue 
analgesia 
1mg/kg increased 
behavioral side-effects 
9/20 (odd, agitation, 
139 
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      restless)  
Neo-
stigmine 
IT 0, 0.25, 0.5, 0.75 or 
1mcg/kg neostigmine plus 
hyperbaric bupi 0.5% 
1 –12 months; n=73 
(14-15 per group) 
RCT D-B; lower abdo 
or urology (55% 
inguinal hernia) 
0.75 and 1mcg/kg reduced pain 
score and prolonged block 
duration; 
CVS stable; emesis 
(10/73) did not differ 
across groups; apnea 
6/73 (assist ventilation 
and cease propofol) 
171 
 EP-B (C) 2mcg/kg or 4mcg/kg plus 
levobupi 0.25% 1ml/kg vs 
levobupi 0.25% 1ml/kg 
5 mths – 5 years; 
n=60 
RCT: lwr abdo or 
inguinal (45% inguinal 
hernia) 
2 and 4mcg/kg decrease pain 
score to 24hrs, prolong analgesia 
PONV 4mcg/kg 3/20 
(n.s.); CVS stable 
162 
 
IT: intrathecal; EP-B: epidural bolus administration; EP-I: epidural infusion; (L): lumbar injection; (L/T): lumbar or thoracic insertion/injection; (C): caudal injection; n.s. not statistically significant 
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Table 3: Comparison of intrathecal doses assessed in neonatal humans and rats  
expressed in terms of total dose, body mass, body surface area, CSF volume and CSF turn over. 
  Analgesic Dose 
  Dosing Metric Human 
Newborn 
Neonatal Rat Pup (3-5 day) 
Body 
Measures 
    
 Neonatal Body 
weight (Kg) 
 3500g 12g 
 Body surface area 
(M*2) 
 
2 
Ne o n ate =  0.2m 
20kg=0.8; 60kg adult=1.6 
304 
0.0035m2 
304; 
P1=0.0025; P7=0.0045; P21=0.0094 
Adult 150g=0.025 279 
 CSF volume -mL  5 0
3 0 5  
306 
0.12 
 CSF Turn over 
(mcL/min ) 
 25mls/day 305 
17mcl/min 
1.05mls/hr 
50mcl/day 
306 
0.34mcl/min 
0.02mls/hr 
Analgesics   Analgesic dose Analgesic dose MTD or toxic dose 
 Morphine T o tal dose  -mcg 2 4 .5 -7 0  0.12mcg 36 
  mcg/kg 
725 
2 0 2 2 , 3 0 7  
186 
10 
3000 (3mg/kg) 
  mg/M•2 0 .1 2 – 0.35  0.034 10.3 
  mcg/mL CSF Vol 0.5 –1.4 1 (2x) 300 (600x) 
  mcg per mcl/min CSF Turnover 1.44 Ð4.1 0.35 106 
  Elimination mcg/ml x ml/hr 0 .5 3 – 1.48  0.02 6 
 Ketamine Total dose-mcg 350 36 120 
  mcg/kg IT ~100 ¤ 
137 
ED: 500 -1000 98 
3000 (3mg/kg) 10,000 (10mg/kg) 
  mg/M•2 1.75 10.2 3.42 
  mcg/mL CSF Vol 7 300 (42x) 1000 (142x) 
  mcg per mcl/min CSF Turnover 20.1 105 1000 
  Elimination mcg/ml x ml/hr = 
mcg/hr 
7.3 6 20 
 Clonidine Total dose-mcg 3.5 0.36 120 
  mcg/kg 
27 
1 
30 10,000mcg/kg 
10mg/kg 
  mg/M•2 0.017 0.103 3.42 
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  mcg/mL CSF Vol 0.07 3 (42x) 1000 (14,285x) 
  mcg per mcl/min CSF Turnover 0.21 1.05 352 
  Elimination mcg/ml x ml/hr = 
mcg/hr 
0.07 0.06 200 
 Bupivacaine Total dose-mcg 1750 -3500 60  
  mg/kg 
2 8 8 2 4  
0.5 – 1 3 . 7 5 7 6  
0.5% solution 
*P7: 16 g  
  mg/M•2 8 .7 5 – 17 .5  13.3  
  mcg/mLCSF Vol 35 - 70 500 (7-14x)  
  Mcg per mcl/min CSF Turnover 102- 205 176  
  Elimination mcg/ml x ml/hr = 
mcg/hr 
37-73 10  
Reference shown in parentheses § adult analgesic doses: 0.2-0.5mg/kg epidural analgesia; 0.1mg/kg intrathecal. As 0.5mg/kg caudal epidural also analgesic in neonate,  
assume 20% dose effective intrathecal  
 
